Purpose: The purpose of this investigation was to synthesize a series of carbonate and carbamate derivatives of 4-demethylpenclomedine (DM-PEN), the major plasma non-toxic metabolite of penclomedine (PEN) seen in patients. DM-PEN has been observed to be an active antitumor agent in mouse human xenograft tumor models and non-neurotoxic in a rat model, however, activity in intracranially implanted human glioma xenograft models have not been reported. The major goal was to identify derivatives that are active in brain tumors. Methods: Derivatives were prepared from DM-PEN and evaluated in vivo against human U251 glioblastoma, D54 glioblastoma and MX-1 breast tumor xenografts and mammary tumor 16/C that were implanted in the mammary fat pad or intracranially (IC). Results: Carbonate and carbamate derivatives were found to be superior to DM-PEN against IC growing human glioblastoma xenografts. Conclusion: The activity of the carbonates and carbamates against human tumor xenografts in vivo suggests consideration of these two series of derivatives of DM-PEN for clinical development. © 2009 Springer-Verlag.
CITATION STYLE
Morgan, L. R., Struck, R. F., Waud, W. R., Leblanc, B., Rodgers, A. H., & Jursic, B. S. (2009). Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemotherapy and Pharmacology, 64(4), 829–835. https://doi.org/10.1007/s00280-009-0933-9
Mendeley helps you to discover research relevant for your work.